---
title: "Kamada Receives FDA Approval For In-House Rabies Virus Neutralization Testing Laboratory"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288277915.md"
description: "Kamada Ltd. announced that the U.S. FDA has approved its new in-house rabies virus neutralization testing laboratory. This approval allows Kamada to conduct specialized tests internally, supporting its commercial product KEDRAB and clinical programs while improving quality control and efficiency. The company aims to reduce reliance on external facilities. Following the announcement, Kamada's stock (KMDA) showed slight movement, closing at $7.81."
datetime: "2026-06-01T12:55:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288277915.md)
  - [en](https://longbridge.com/en/news/288277915.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288277915.md)
---

# Kamada Receives FDA Approval For In-House Rabies Virus Neutralization Testing Laboratory

(RTTNews) - Kamada Ltd. (KMDA), a biopharmaceutical company specializing in plasma-derived therapies, announced that the U.S. FDA has approved its new in-house rabies virus neutralization testing laboratory.

Rabies remains a fatal viral disease without timely treatment, and neutralization assays are critical for evaluating the potency of rabies immunoglobulin products. Kamada's new laboratory will allow the company to conduct these specialized tests internally ensuring faster turnaround times and greater control over quality standards.

The FDA approval enables Kamada to perform rabies virus neutralization assays (RVNA) in support of its commercial rabies immunoglobulin product KEDRAB, which is marketed in the U.S. through its partner Kedrion Biopharma. The facility will also support ongoing clinical development programs and regulatory submissions.

Amir London, CEO of Kamada, said the FDA approval strengthens the company's quality control and regulatory capabilities while supporting both commercial and clinical programs.

The company noted that the new laboratory will reduce reliance on external testing facilities, improve efficiency, and provide greater flexibility in meeting regulatory requirements. Kamada continues to expand its portfolio of plasma-derived therapies across infectious diseases, immunology, and critical care.

KMDA has traded between $6.50 and $9.35 over the past years. The stock closed Friday's trading (May 29, 2026) at $7.81, down 0.64%. In pre-market trading the stock is at $7.89, up 1.02%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [KMDA.US](https://longbridge.com/en/quote/KMDA.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [OraSure wins FDA clearance for Colli-Pee Dx urine kit for Roche cobas systems](https://longbridge.com/en/news/289471276.md)
- [Rupert Resources Obtains Final Court Approval and Announces Expected Closing Date for Arrangement With Agnico Eagle | AEM Stock News](https://longbridge.com/en/news/289504861.md)
- [Argenx (ENXTBR:ARGX) Stock Valuation After Expanded FDA Approval For Vyvgart And Pipeline Progress](https://longbridge.com/en/news/289661572.md)
- [US FDA approves Pfizer's bleeding disorder drug for children](https://longbridge.com/en/news/289042377.md)
- [Tempus AI (TEM) Valuation Check As FDA Approval And New AI Tools Shape Growth Expectations](https://longbridge.com/en/news/289302838.md)